Aviance Capital Partners LLC Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Aviance Capital Partners LLC decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 75.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,218 shares of the biopharmaceutical company's stock after selling 15,684 shares during the period. Aviance Capital Partners LLC's holdings in Gilead Sciences were worth $585,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of GILD. Redwood Financial Network Corp boosted its holdings in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 98 shares during the period. Nicolet Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after acquiring an additional 100 shares during the period. Peak Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after acquiring an additional 100 shares during the period. Perkins Coie Trust Co boosted its holdings in shares of Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after acquiring an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. boosted its holdings in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $0.03 during trading hours on Monday, reaching $111.78. The company had a trading volume of 6,955,665 shares, compared to its average volume of 7,703,268. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a one year low of $66.34 and a one year high of $119.96. The firm has a market cap of $139.05 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The business has a fifty day moving average price of $107.12 and a 200-day moving average price of $104.25.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company posted ($1.32) EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.83%. Gilead Sciences's payout ratio is presently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the transaction, the insider directly owned 120,168 shares in the company, valued at $13,238,908.56. This trade represents a 2.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 58,500 shares of company stock valued at $6,340,745 in the last ninety days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.